Single-dose azithromycin for the treatment of cholera in adults

New England Journal of Medicine

Volumn 354, Issue 23, 2006, Pages 2452-2462

  Saha, Debasish ^a,d   Karim, Mohammad M ^a   Khan, Wasif A ^a   Ahmed, Sabeena ^a   Salam, Mohammed A ^a   Bennish, Michael L ^b,c  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ICDDRB Clinical Sciences Division   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FURAZOLIDONE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FECES ANALYSIS; FECES CULTURE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIBRIO CHOLERAE; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BANGLADESH; CHOLERA; CIPROFLOXACIN; COMBINED MODALITY THERAPY; DIARRHEA; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FLUID THERAPY; HUMANS; MALE; TREATMENT OUTCOME; VIBRIO CHOLERAE; VOMITING;

EID: 33744959049     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa054493     Document Type: Article

References (27)

1. Weekly epidemiological record: cholera 2004. Geneva: World Health Organization, August 5, 2005. (Accessed May 12, 2006, at http://whqlibdoc.who. int/wer/WHO_WER_2005/80_261-268(no31).pdf.)
2. Greenough WB III, Gordon RS Jr, Rosenberg IS, Davies BI, Benenson AS. Tetracycline in the treatment of cholera. Lancet 1964;41:355-7.
3. Garg P, Chakraborty S, Basu I, et al. Expanding multiple antibiotic resistance among clinical strains of Vibrio cholerae isolated from 1992-7 in Calcutta, India. Epidemiol Infect 2000;124:393-9.
4. Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967;36:871-83.
5. Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990;300:1619-21.
6. Islam MR. Single dose tetracycline in cholera. Gut 1987;28:1029-32.
7. Sack DA, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. Antimicrob Agents Chemother 1978;14:462-4.
8. Siddique AK, Zaman K, Majumder Y, et al. Simultaneous outbreaks of contrasting drug resistant classic and El Tor Vibrio cholerae O1 in Bangladesh. Lancet 1989;2:396.
9. Siddique AK, Salam A, Islam MS, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995;345:359-61.
10. The treatment of diarrhoea: a manual for physicians and other senior health workers. Geneva: World Health Organization, 2005. (Accessed May 12, 2006, at http://www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/ ISBN_92_4_159318_0.pdf.)
11. Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002;360:1722-7.
12. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91:5S-11S.
13. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91:40S-45S.
14. Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139. Lancet 1996;348:296-300.
15. Makuch RW, Johnson MF. Some issues in the design and interpretation of 'negative' clinical studies. Arch Intern Med 1986;146:986-9.
16. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
17. Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991;29:533-8.
18. Brown DF, Brown L. Evaluation of the E test, a novel method of quantifying antimicrobial activity. J Antimicrob Chemother 1991;27:185-90.
19. Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005;366:1085-93. [Erratum, Lancet 2005;366:1054-5.]
20. Rabbani GH, Islam MR, Butler T, Shahrier M, Alam K. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial. Antimicrob Agents Chemother 1989;33:1447-50.
21. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
22. Approved standards M2-A6: performance standards for antimicrobial disk susceptibility tests. 6th ed. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1997.
23. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003;37:75-81.
24. Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 1995;39:2442-5.
25. Emergence of a unique, multi-drug resistant strain of Vibrio cholerae O1 in Bangladesh. Health Sci Bull 2005;3:1-20. (Accessed May 12, 2006, at http://www. icddrb.org/pub/publication.jsp?classificationID=56&pubID=6298.)
26. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: Centers for Disease Control and Prevention, 1999. (Accessed May 12, 2006, at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/cholera/top.pdf.)
27. Wenzel RP. The antibiotic pipeline - challenges, costs, and values. N Engl J Med 2004;351:523-6.